Nivolumab in Treating Patients With Relapsed or Refractory Peripheral T-cell Lymphoma

PHASE2TerminatedINTERVENTIONAL
Enrollment

12

Participants

Timeline

Start Date

May 17, 2017

Primary Completion Date

May 29, 2019

Study Completion Date

May 29, 2019

Conditions
Blastic Plasmacytoid Dendritic Cell NeoplasmHepatosplenic T-Cell LymphomaHTLV-1 InfectionNK-Cell Lymphoma, UnclassifiablePrimary Systemic Anaplastic Large Cell Lymphoma, ALK-NegativeRecurrent Adult T-Cell Leukemia/LymphomaRecurrent Anaplastic Large Cell LymphomaRecurrent Angioimmunoblastic T-cell LymphomaRecurrent Enteropathy-Associated T-Cell LymphomaRecurrent Mycosis FungoidesRefractory Adult T-Cell Leukemia/LymphomaRefractory Anaplastic Large Cell LymphomaRefractory Angioimmunoblastic T-cell LymphomaRefractory Enteropathy-Associated T-Cell LymphomaRefractory Mycosis FungoidesRefractory Nasal Type Extranodal NK/T-Cell LymphomaRefractory Peripheral T-Cell Lymphoma, Not Otherwise Specified
Interventions
OTHER

Laboratory Biomarker Analysis

Correlative studies

BIOLOGICAL

Nivolumab

Given IV

Trial Locations (1)

55905

Mayo Clinic, Rochester

Sponsors

Lead Sponsor

All Listed Sponsors
collaborator

National Cancer Institute (NCI)

NIH

lead

Mayo Clinic

OTHER

NCT03075553 - Nivolumab in Treating Patients With Relapsed or Refractory Peripheral T-cell Lymphoma | Biotech Hunter | Biotech Hunter